The impaired hepatic lipid metabolism in NAFLD is exhibited by dysregulated PPARα and SREBP-1c signaling pathways, which are central transcription factors associated with lipid degradation and de novo lipogenesis. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.